Letters to the Editor [4]

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 208-210

  Goodin, Douglas S ^a   Hurwitz, B ^b   Noronha, A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC AGENT; BETA1 INTERFERON; NEUTRALIZING ANTIBODY;

DRUG MANUFACTURE; FLU LIKE SYNDROME; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOASSAY; LETTER; MULTIPLE SCLEROSIS; NONRESPONSE BIAS; TREATMENT RESPONSE;

EID: 39149090015     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Goodin DS, Hurwitz B, Noronha A: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173-187.
2. Sorensen PS, Koch-Henriksen N, Ross C, et al: Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
3. Francis GS, Rice GP, Alsop JC: Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
4. Kappos L, Clanet M, Sandberg-Wollheim M, Radue, et al: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
5. Clanet M, Radue EW, Kappos L, et al: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517.
6. Sorensen PS, Ross C, Clemmesen KM, et al: Clinical importance of neutralising antibodies against interferon beto. in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.